Revolution pushes home its pan-KRAS advantage
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
ESMO 2023 – Revolution sets the bar in pan-KRAS inhibition
But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.
Triple meeting 2023 – Revolution’s KRAS revolution promise draws fans
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.
Triple meeting 2023 preview – firsts for Amgen and Novartis
But Repare and Black Diamond still have rebuilding to do.
Mirati secures an independent future
Mirati raises $300m as its chief exec departs. What’s not to like?
